Coherus Oncology, Inc.
CHRS
Rank in Stocks
#18656
Coherus Oncology, Inc. is a biopharmaceutical company primarily focused on the... Coherus Oncology, Inc. is a biopharmaceutical company primarily focused on the research, development, and commercialization of cancer immunotherapies across the United States. The company's commercialized products include several biosimilar therapies. These comprise UDENYCA, a long-acting granulocyte-colony stimulating factor biosimilar to Neulasta; YUSIMRY, an equivalent to Humira, prescribed for inflammatory conditions like rheumatoid arthritis, psoriasis, and Crohn's disease, which are characterized by heightened tumor necrosis factor (TNF) production; and CIMERLI, a Lucentis biosimilar aimed at treating specific ophthalmic disorders such as neovascular age-related macular degeneration, macular edema, and diabetic retinopathy. Beyond its commercial products, Coherus maintains a robust pipeline of investigational immunotherapies. This includes LOQTORZI, a novel, next-generation programmed death receptor-1 (PD-1) inhibitor; Casdozokitug, a recombinant human immunoglobulin G1 (IgG1) monoclonal antibody designed to target interleukin 27; CHS-114, a highly specific human afucosylated IgG1 monoclonal antibody targeting a chemokine receptor prevalent on Treg cells in the tumor microenvironment (TME); CHS-1000, an anti-ILT4 monoclonal antibody aimed at solid tumors; and GSK4381562, an antibody engineered to target CD112R on tumor cells. To support its endeavors, the company has forged several strategic alliances. These encompass a co-development and commercialization pact with Junshi Biosciences for toripalimab, as well as agreements with Surface and Adimab LLC. Its licensing portfolio includes arrangements with Bioeq AG, Genentech, Inc., Surface, and Vaccinex, Inc. Furthermore, Coherus has out-licensing agreements with Novartis Institutes for Biomedical Research, Inc. and GlaxoSmithKline Intellectual Property No. 4 Limited. Founded in 2010, the company currently operates as Coherus BioSciences, Inc., but is slated to officially rebrand as Coherus Oncology, Inc. in May 2025. Its headquarters are located in Redwood City, California.
Share Price
$0.8176
Last synced: 2026-11-09
Market Cap
$126.32M
Change (1 day)
6.18%
Change (1 year)
-39.44%
Country
Stock data: Financial Modeling PrepΒ·Updated Β·Not investment adviceΒ·How we calculate this
Trade Coherus Oncology, Inc. (CHRS)
Category
Healthcare
Operating Margin for Coherus Oncology, Inc. (CHRS)
Operating Margin as of November 2026 TTM: -307.43%
According to Coherus Oncology, Inc.'s latest financial reports, its current operating margin (TTM) is -307.43%. At the end of 2025 the company had an operating margin of -425.72%.
Operating Margin history for Coherus Oncology, Inc. from 2012 to 2026
Operating Margin at the end of each year
| Year | Operating Margin | Change |
|---|---|---|
| 2026 (TTM) | -307.43% | -27.79% |
| 2025 | -425.72% | 917.74% |
| 2024 | -41.83% | -47.04% |
| 2023 | -78.99% | -35.11% |
| 2022 | -121.72% | 50.64% |
| 2021 | -80.80% | -345.97% |
| 2020 | 32.85% | 8.52% |
| 2019 | 30.27% | -100.23% |
| 2018 | -13,137.28% | -11.94% |
| 2017 | -14,918.77% | 24,365.02% |
| 2016 | -60.98% | -91.64% |
| 2015 | -729.23% | 250.69% |
| 2014 | -207.94% | -84.11% |
| 2013 | -1,308.36% | -35.50% |
| 2012 | -2,028.33% | 0.00% |
Operating Margin for similar companies or competitors
| Company | Operating Margin | Operating Margin Difference | Country |
|---|---|---|---|
| 38.59% | -100.13% |
US
|
|
| -149.01% | -99.52% |
US
|
|
| 25.57% | -100.08% |
AU
|
|
| 31.23% | -100.10% |
BE
|
|
| 29.35% | -100.10% |
NL
|
What is a company's Operating Margin?
The operating margin is a key indicator to assess the profitability of a company. Higher operating margins are generaly better as they show that a company is able to sell its products or services for much more than their production costs. The operating margin is calculated by dividing a company's earnings by its revenue.
Questions about Coherus Oncology, Inc.'s operating margin
What is Coherus Oncology, Inc.'s operating margin?
Coherus Oncology, Inc.'s operating margin is -307.43%, as of Nov 2026.
What was Coherus Oncology, Inc.'s operating margin in 2025?
In 2025, Coherus Oncology, Inc.'s operating margin was -425.72%, compared with -41.83% in 2024.
How has Coherus Oncology, Inc.'s operating margin changed since 2020?
From 2020 to 2025, Coherus Oncology, Inc.'s operating margin was highest in 2020 (32.85%) and lowest in 2025 (-425.72%).
How does Coherus Oncology, Inc.'s operating margin compare with similar companies?
Coherus Oncology, Inc.'s operating margin (-307.43%) is lower than that of all 5 similar companies listed above. The highest among them is Vertex Pharmaceuticals Incorporated, with 38.59%.